Research article summary:

A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings.

Abstract Extract:
There appears to be an absence of large-scaled clinical trials that have examined the efficacy of Ginkgo biloba extract on the neuropsychological functioning of cognitively intact older adults. The importance of such clinical research appears paramount ... (Full abstract text below)

Published 2002Aug in Journal: Hum Psychopharmacol (Language : eng)

Full Pubmed Extract

This information was retrieved, real-time, on your behalf from the public area of the Pubmed website:

1. Hum Psychopharmacol. 2002 Aug;17(6):267-77

A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings.

Mix JA, Crews WD

Department of Health Sciences, Liberty University, Lynchburg, Virginia 24502, USA.

There appears to be an absence of large-scaled clinical trials that have examined the efficacy of Ginkgo biloba extract on the neuropsychological functioning of cognitively intact older adults. The importance of such clinical research appears paramount in light of the plethora of products containing Ginkgo biloba that are currently being widely marketed to predominantly cognitively intact adults with claims of enhanced cognitive performances. The purpose of this research was to conduct the first known, large-scaled clinical trial of the efficacy of Ginkgo biloba extract (EGb 761) on the neuropsychological functioning of cognitively intact older adults. Two hundred and sixty-two community-dwelling volunteers (both male and female) 60 years of age and older, who reported no history of dementia or significant neurocognitive impairments and obtained Mini-Mental State Examination total scores of at least 26, were examined via a 6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel-group, clinical trial. Participants were randomly assigned to receive either Ginkgo biloba extract EGb 761(n = 131; 180 mg/day) or placebo (n = 131) for 6 weeks. Efficacy measures consisted of participants' raw change in performance scores from pretreatment baseline to those obtained just prior to termination of treatment on the following standardized neuropsychological measures: Selective Reminding Test (SRT), Wechsler Adult Intelligence Scale-III Block Design (WAIS-III BD) and Digit Symbol-Coding (WAIS-III DS) subtests, and the Wechsler Memory Scale-III Faces I (WMS-III FI) and Faces II (WMS-III FII) subtests. A subjective Follow-up Self-report Questionnaire was also administered to participants just prior to termination of the treatment phase. Analyses of covariance indicated that cognitively intact participants who received 180 mg of EGb 761 daily for 6 weeks exhibited significantly more improvement on SRT tasks involving delayed (30 min) free recall (p < 0.04) and recognition (p < 0.01) of noncontextual, auditory-verbal material, compared with the placebo controls. The EGb 761 group also demonstrated significantly greater improvement on the WMS-III FII subtest assessing delayed (30 min) recognition (p < 0.025) of visual material (i.e. human faces), compared with the placebo group. However, based on the significant difference (p < 0.03) found between the two groups' pretreatment baseline scores on the WMS-III FII, this result should be interpreted with caution. An examination of the participants' subjective ratings of their overall abilities to remember by treatment end on the Follow-up Self-report Questionnaire also revealed that significantly more (p = 0.05) older adults in the EGb 761 group rated their overall abilities to remember by treatment end as 'improved' compared with the placebo controls. Overall, the results from both objective, standardized, neuropsychological tests and a subjective, follow-up self-report questionnaire provided complementary evidence of the potential efficacy of Ginkgo biloba EGb 761 in enhancing certain neuropsychological/memory processes of cognitively intact older adults, 60 years of age and over.

PMID : 12404671 [PubMed - Indexed for MEDLINE]

This information is obtained from the National Library of Medicine (NLM). Abstract text and other information may be subject to copyright. Type "NLM copyright" into Google for more information.

Full Author Information

First Name	LastName	Initials
Joseph A	Mix	JA
W David	Crews	WD

Affiliation: Department of Health Sciences, Liberty University, Lynchburg, Virginia 24502, USA.

3rd Party provider links

Click the links below to go to related 3rd party information:

MESH categories and related page links

This article was linked to the MESH categories shown on the left below. The links on the right are related Memletics pages.

Links for this article

For links to places where you can get the full text of this article see links. Note there may be a subscription or fee required for access to the full text.

New! Using similar technology to this site, we have launched find-health-articles.com, targeting over 1 million health research article abstracts.

Here are some articles related to this one (by title keywords):

Cognitive improvement in mild to moderate Alzheimers dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.

Attitudes of patients with schizophrenia toward placebo-controlled clinical trials.

A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.

A phase I study of AIT-082 in healthy elderly volunteers.

Ondansetron in the treatment of cognitive decline in Alzheimer dementia.

Effects of 5 weeks of administration of fluoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood.

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia.

Donepezil and flight simulator performance: effects on retention of complex skills.

Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects.

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system.

>>> Get more research article abstracts like these, or browse abstracts.

Keywords in this article:

abilities, absence, administered, adults, age, analyses, appears, assessing, assigned, auditory, based, baseline, bd, biloba, blind, block, caution, certain, change, claims, clinical, coding, cognitively, community, compared, complementary, conduct, consisted, containing, controlled, controls, covariance, currently, daily, day, delayed, dementia, demonstrated, design, difference, digit, dose, double, ds, dwelling, efficacy, egb, end, enhanced, enhancing, evidence, examination, examined, exhibited, extract, faces, female, fii, first, fixed, following, free, functioning, ginkgo, greater, group, groups, history, human, hundred, iii, impairments, importance, improved, improvement, indicated, intact, intelligence, interpreted, involving, known, large, least, light, male, marketed, material, measures, memory, mental, mini, more, neurocognitive, neuropsychological, noncontextual, objective, older, parallel, paramount, participants, performances, phase, placebo, plethora, potential, predominantly, pretreatment, prior, processes, products, provided, purpose, questionnaire, randomized, randomly, ratings, raw, recall, receive, received, recognition, remember, reminding, reported, research, result, results, revealed, scaled, scores, selective, self, significant, sixty, srt, standardized, state, subjective, subtests, symbol, tasks, termination, test, total, trials, two, verbal, via, visual, volunteers, wais, wechsler, week, weeks, who, widely, wms, years

Also, see our new free speed reading online course (beta version)